The landmark FOURIER trial, a large multicenter, randomized, double-blind, placebo-controlled study involving 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD), provided robust evidence for the efficacy of PCSK9 inhibition with evolocumab. Here, PCSK9 is linked to atherosclerosis.